Literature DB >> 33963769

International trends in incidence of osteosarcoma (1988-2012).

Gabriela A Rojas1, Aubrey K Hubbard2, Brandon J Diessner2, Karina B Ribeiro1, Logan G Spector2,3.   

Abstract

Osteosarcoma (OS) is the most common primary bone tumor in children and adolescents. The etiology of OS is largely unknown but may be informed by comparisons of incidence and trends between geographic regions. Using the Cancer Incidence in Five Continents (CI5) data from 1988 to 2012, we present OS age-standardized incidence rates (ASRs; cases/million) and average annual percent change (AAPC) and 95% confidence interval (CI) by geographic region among the age groups 0-9, 10-19, 20-29, 30-59, 60-79, 0-79. Among the 10-19 age group, we also used the most recent data (2008-2012) to present the ASRs for each country. We observed little variation in OS incidence between geographic regions in 2008-2012 across all age groups. Overall, the ASR for 0-79 ranged from 2 cases per million in Southern Asia to 4.2 in Sub-Saharan Africa. A bimodal distribution in incidence was observed with peaks in the 10-19 and 60-79 age groups across all regions over time. Overall, OS incidence was relatively stable across 1988-2012 with the only statistically significant increases in the 0-79 age group observed in Eastern Asia (AAPC: 1.8; 95% CI: 0.6, 1.9) and Sub-Saharan Africa (AAPC: 3.1; 95% CI: 0.5, 5.8). The small variation in incidence between regions and the stability in incidence over time suggests that OS carcinogenesis is not influenced by environmental or time-varying exposures.
© 2021 UICC.

Entities:  

Keywords:  bone cancer; epidemiology; incidence; international; osteosarcoma

Mesh:

Year:  2021        PMID: 33963769      PMCID: PMC9137041          DOI: 10.1002/ijc.33673

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.316


  41 in total

1.  Height as a risk factor for osteosarcoma.

Authors:  Alessandra Longhi; Andrea Pasini; Alessandro Cicognani; Federico Baronio; Andrea Pellacani; Nicola Baldini; Gaetano Bacci
Journal:  J Pediatr Hematol Oncol       Date:  2005-06       Impact factor: 1.289

2.  Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort.

Authors:  Phuong L Mai; Ana F Best; June A Peters; Rosamma M DeCastro; Payal P Khincha; Jennifer T Loud; Renée C Bremer; Philip S Rosenberg; Sharon A Savage
Journal:  Cancer       Date:  2016-08-06       Impact factor: 6.860

Review 3.  Tumor Syndromes Predisposing to Osteosarcoma.

Authors:  Meera Hameed; Diana Mandelker
Journal:  Adv Anat Pathol       Date:  2018-07       Impact factor: 3.875

4.  Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions.

Authors:  Cristian Tomasetti; Bert Vogelstein
Journal:  Science       Date:  2015-01-02       Impact factor: 47.728

5.  Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years.

Authors:  Graça M Dores; Catherine Metayer; Rochelle E Curtis; Charles F Lynch; E Aileen Clarke; Bengt Glimelius; Hans Storm; Eero Pukkala; Flora E van Leeuwen; Eric J Holowaty; Michael Andersson; Tom Wiklund; Timo Joensuu; Mars B van't Veer; Marilyn Stovall; Mary Gospodarowicz; Lois B Travis
Journal:  J Clin Oncol       Date:  2002-08-15       Impact factor: 44.544

6.  Bone cancer incidence by morphological subtype: a global assessment.

Authors:  Patricia C Valery; Mathieu Laversanne; Freddie Bray
Journal:  Cancer Causes Control       Date:  2015-06-09       Impact factor: 2.506

7.  International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons.

Authors:  Lisa Mirabello; Rebecca J Troisi; Sharon A Savage
Journal:  Int J Cancer       Date:  2009-07-01       Impact factor: 7.396

8.  Genetic determinants of childhood and adult height associated with osteosarcoma risk.

Authors:  Chenan Zhang; Libby M Morimoto; Adam J de Smith; Helen M Hansen; Julio Gonzalez-Maya; Alyson A Endicott; Ivan V Smirnov; Catherine Metayer; Qingyi Wei; William C Eward; Joseph L Wiemels; Kyle M Walsh
Journal:  Cancer       Date:  2018-10-12       Impact factor: 6.921

9.  Association between Adult Height and Risk of Colorectal, Lung, and Prostate Cancer: Results from Meta-analyses of Prospective Studies and Mendelian Randomization Analyses.

Authors:  Nikhil K Khankari; Xiao-Ou Shu; Wanqing Wen; Peter Kraft; Sara Lindström; Ulrike Peters; Joellen Schildkraut; Fredrick Schumacher; Paolo Bofetta; Angela Risch; Heike Bickeböller; Christopher I Amos; Douglas Easton; Rosalind A Eeles; Stephen B Gruber; Christopher A Haiman; David J Hunter; Stephen J Chanock; Brandon L Pierce; Wei Zheng
Journal:  PLoS Med       Date:  2016-09-06       Impact factor: 11.069

10.  Incidence and survival of childhood bone cancer in northern England and the West Midlands, 1981-2002.

Authors:  R Eyre; R G Feltbower; E Mubwandarikwa; H C Jenkinson; S Parkes; J M Birch; T O B Eden; P W James; P A McKinney; M S Pearce; R J Q McNally
Journal:  Br J Cancer       Date:  2009-01-13       Impact factor: 7.640

View more
  8 in total

Review 1.  Surgical Treatment of Bone Sarcoma.

Authors:  Felix Bläsius; Heide Delbrück; Frank Hildebrand; Ulf Krister Hofmann
Journal:  Cancers (Basel)       Date:  2022-05-29       Impact factor: 6.575

2.  Identification of the Transcription Co-Factor-Related Gene Signature and Risk Score Model for Osteosarcoma.

Authors:  Zhijian Jin; Jintao Wu; Jianwei Lin; Jun Wang; Yuhui Shen
Journal:  Front Genet       Date:  2022-06-06       Impact factor: 4.772

3.  Comprehensive Analysis of a Ferroptosis-Related lncRNA Signature for Predicting Prognosis and Immune Landscape in Osteosarcoma.

Authors:  Yiming Zhang; Rong He; Xuan Lei; Lianghao Mao; Zhengyu Yin; Xinyu Zhong; Wenbing Cao; Qiping Zheng; Dapeng Li
Journal:  Front Oncol       Date:  2022-06-28       Impact factor: 5.738

4.  Integrated analyses of an RNA binding protein-based signature related to tumor immune microenvironment and candidate drugs in osteosarcoma.

Authors:  Abdulraheem Gul Mohammad; Dapeng Li; Rong He; Xuan Lei; Lianghao Mao; Bing Zhang; Xinyu Zhong; Zhengyu Yin; Wenbing Cao; Wenchao Zhang; Ruoxuan Hei; Qiping Zheng; Yiming Zhang
Journal:  Am J Transl Res       Date:  2022-04-15       Impact factor: 3.940

5.  A Novel Pyroptosis-Related Signature for Predicting Prognosis and Indicating Immune Microenvironment Features in Osteosarcoma.

Authors:  Yiming Zhang; Rong He; Xuan Lei; Lianghao Mao; Pan Jiang; Chenlie Ni; Zhengyu Yin; Xinyu Zhong; Chen Chen; Qiping Zheng; Dapeng Li
Journal:  Front Genet       Date:  2021-11-26       Impact factor: 4.599

6.  Nomogram predicting leukopenia in osteosarcoma after high-dose methotrexate chemotherapy.

Authors:  Haixiao Wu; Guijun Xu; Zhijun Li; Yao Xu; Yile Lin; Vladimir P Chekhonin; Karl Peltzer; Jun Wang; Shu Li; Huiyang Li; Jin Zhang; Yuan Xue; Wenjuan Ma; Xin Wang; Chao Zhang
Journal:  Aging (Albany NY)       Date:  2022-05-31       Impact factor: 5.955

Review 7.  Insight into the interplay between mitochondria-regulated cell death and energetic metabolism in osteosarcoma.

Authors:  Hong Toan Lai; Nataliia Naumova; Antonin Marchais; Nathalie Gaspar; Birgit Geoerger; Catherine Brenner
Journal:  Front Cell Dev Biol       Date:  2022-08-22

8.  Frequently expressed glypican-3 as a promising novel therapeutic target for osteosarcomas.

Authors:  Jun-Hua Nie; Tao Yang; Hong Li; Sheng Li; Ting-Ting Li; Hai-Shan Ye; Meng-Di Lu; Xiao Chu; Guo-Qing Zhong; Jie-Long Zhou; Mo-Li Wu; Yu Zhang; Jia Liu
Journal:  Cancer Sci       Date:  2022-08-21       Impact factor: 6.518

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.